Ocugen to Present at Industry and Investor Conferences in October 2025
Ocugen (NASDAQ: OCGN), a biotechnology company focused on gene therapies for blindness diseases, announced its participation in three major industry conferences in October 2025. The company will present at the Cell & Gene Meeting on the Mesa, Chardan's 9th Annual Genetic Medicines Conference, and the 2025 Maxim Growth Summit.
CEO Dr. Shankar Musunuri highlighted the company's goal of achieving three BLAs in the next three years. Executive Vice President Abhi Gupta will present a company update at Meeting on the Mesa, while Dr. Musunuri will participate in panel discussions at the Chardan and Maxim conferences. The events will also include one-on-one meetings with company leadership.
Ocugen (NASDAQ: OCGN), una società biotecnologica focalizzata sulle terapie geniche per malattie della vista, ha annunciato la sua partecipazione a tre importanti conferenze di settore nell'ottobre 2025. L'azienda interverrà al Cell & Gene Meeting on the Mesa, al Chardan's 9th Annual Genetic Medicines Conference e al 2025 Maxim Growth Summit.
Il CEO, il dottor Shankar Musunuri, ha evidenziato l'obiettivo di ottenere tre BLAs nei prossimi tre anni. Il vicepresidente esecutivo Abhi Gupta presenterà un aggiornamento sull'azienda al Meeting on the Mesa, mentre il dottor Musunuri parteciperà a workshop/panel di discussione alle conferenze di Chardan e Maxim. Gli eventi includeranno anche incontri individuali con i vertici dell'azienda.
Ocugen (NASDAQ: OCGN), una empresa biotecnológica centrada en terapias génicas para enfermedades de la vista, anunció su participación en tres importantes conferencias del sector en octubre de 2025. La compañía presentará en Cell & Gene Meeting on the Mesa, Chardan's 9th Annual Genetic Medicines Conference y el 2025 Maxim Growth Summit.
El CEO, el Dr. Shankar Musunuri, destacó el objetivo de lograr tres BLAs en los próximos tres años. El vicepresidente ejecutivo Abhi Gupta presentará una actualización de la empresa en Meeting on the Mesa, mientras que el Dr. Musunuri participará en paneles en las conferencias de Chardan y Maxim. Los eventos también incluirán reuniones uno a uno con la dirección de la empresa.
Ocugen (NASDAQ: OCGN)은 실명 질환에 대한 유전자 치료에 중점을 둔 생명공학 기업으로, 2025년 10월에 열리는 세 개의 주요 업계 컨퍼런스에 참가한다고 발표했습니다. 회사는 Cell & Gene Meeting on the Mesa, Chardan's 9th Annual Genetic Medicines Conference, 그리고 2025 Maxim Growth Summit에서 발표합니다.
CEO인 Dr. Shankar Musunuri는 향후 3년 내 세 개의 BLA를 달성하겠다는 목표를 강조했습니다. Executive Vice President Abhi Gupta가 Meeting on the Mesa에서 회사 업데이트를 발표하고, Musunuri 박사는 Chardan 및 Maxim 컨퍼런스의 패널 토론에 참여할 예정입니다. 행사에는 회사 경영진과의 일대일 면담도 포함됩니다.
Ocugen (NASDAQ: OCGN), une entreprise biotechnologique axée sur les thérapies géniques pour les maladies de la vue, a annoncé sa participation à trois grandes conférences industrielles en octobre 2025. L'entreprise interviendra lors du Cell & Gene Meeting on the Mesa, de la Chardan's 9th Annual Genetic Medicines Conference et du 2025 Maxim Growth Summit.
Le PDG, le Dr Shankar Musunuri, a souligné l'objectif d'atteindre trois BLAs au cours des trois prochaines années. Le vice-président exécutif Abhi Gupta présentera une mise à jour de l'entreprise au Meeting on the Mesa, tandis que le Dr Musunuri participera à des panels lors des conférences de Chardan et Maxim. Les événements organiseront également des rencontres individuelles avec la direction de l'entreprise.
Ocugen (NASDAQ: OCGN), ein Biotechnologieunternehmen, das sich auf Gentherapien für Blindheitskrankheiten konzentriert, gab seine Teilnahme an drei großen Branchenkonferenzen im Oktober 2025 bekannt. Das Unternehmen wird beim Cell & Gene Meeting on the Mesa, bei der Chardan's 9th Annual Genetic Medicines Conference und dem 2025 Maxim Growth Summit präsentieren.
CEO Dr. Shankar Musunuri hob das Ziel hervor, in den nächsten drei Jahren drei BLAs zu erreichen. Executive Vice President Abhi Gupta wird während des Meeting on the Mesa ein Unternehmensupdate vorstellen, während Dr. Musunuri an Podiumsdiskussionen bei den Konferenzen von Chardan und Maxim teilnehmen wird. Zu den Veranstaltungen gehören auch Einzelgespräche mit der Geschäftsführung.
Ocugen (NASDAQ: OCGN)، شركة تكنولوجيا حيوية تركز على العلاجات الجينية للأمراض العمياء، أعلنت عن مشاركتها في ثلاث مؤتمرات صناعية كبرى في أكتوبر 2025. ستقدم الشركة في Cell & Gene Meeting on the Mesa، وChardan's 9th Annual Genetic Medicines Conference، و2025 Maxim Growth Summit.
أبرز الرئيس التنفيذي الدكتور شنكار موسونوري هدف الشركة بتحقيق ثلاثة BLAs في السنوات الثلاث المقبلة. سيقدم نائب الرئيس التنفيذي أبهي جوبتا تحديثًا للشركة في Meeting on the Mesa، بينما سيشارك الدكتور موسونوري في جلسات نقاش في مؤتمري تشاردان وماكسيم. وستشمل الفعاليات أيضًا لقاءات شخصية مع قيادة الشركة.
Ocugen (NASDAQ: OCGN)，一家专注于治疗致盲疾病的基因疗法的生物技术公司，宣布将于2025年10月参加三场重要行业会议。公司将于Cell & Gene Meeting on the Mesa、Chardan's 9th Annual Genetic Medicines Conference和2025 Maxim Growth Summit进行发言。
首席执行官Shankar Musunuri博士强调了在未来三年内实现三项BLAs的目标。执行副总裁Abhi Gupta将在Meeting on the Mesa上发布公司更新，Musunuri博士将参与Chardan和Maxim两场会议的专题讨论。活动还将包括与公司领导层的一对一会谈。
- None.
- None.
MALVERN, Pa., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that executive leadership will present at the 2025 Cell & Gene Meeting on the Mesa, Chardan’s 9th Annual Genetic Medicines Conference, and the 2025 Maxim Growth Summit.
“These industry and investor meetings provide an excellent forum to share specifically how Ocugen is advancing toward our goal of three BLAs in the next three years,” said Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen. “We are excited to share our contribution toward bringing a new generation of gene therapies to market and engage with potential partners to join us on our journey.”
At Meeting on the Mesa, Abhi Gupta, Executive Vice President, Commercial and Business Development at Ocugen, will present a company update, and Dr. Musunuri will be a featured panelist during the Chardan and Maxim conferences. In addition to these sessions, members of Ocugen’s leadership team will conduct one-on-one meetings to showcase the Company’s business and clinical development strategy.
Details of the presentation and panels are as follows:
| Cell & Gene Meeting on the Mesa—hosted by the Alliance for Regenerative Medicine | |
| Company Presentation | |
| Date: | Monday, October 6, 2025 |
| Time: | 4 p.m. MST |
| Location: | FLW, Ballroom G, Arizona Biltmore, Phoenix, AZ |
| Chardan’s 9th Annual Genetic Medicines Conference | |
| Panel: | In Vivo Gene Therapy: Breaking into Competitive Ophthalmic Indications |
| Date: | Tuesday, October 21, 2025 |
| Time: | 9:30-10:10 a.m. EDT |
| Location: | Reid Salon, 2nd Floor, Lotte Palace Hotel, New York, NY |
| 2025 Maxim Growth Summit | |
| Panel: | Ophthalmology Panel—A Vision of Innovation |
| Date: | Wednesday, October 22, 2025 |
| Time: | 3-4 p.m. EDT |
| Location: | Hard Rock Hotel, New York, NY |
Ocugen is proud to participate in these prestigious events bringing together industry leaders, innovators, and premier institutions to explore the future of medicine and the most impactful ways to deliver innovative therapies to patients.
About Ocugen, Inc.
Ocugen, Inc. is a pioneering biotechnology leader in gene therapies for blindness diseases. Our breakthrough modifier gene therapy platform has the potential to address significant unmet medical need for large patient populations through our gene-agnostic approach. Unlike traditional gene therapies and gene editing, Ocugen’s modifier gene therapies address the entire disease—complex diseases that are potentially caused by imbalances in multiple gene networks. Currently we have programs in development for inherited retinal diseases and blindness diseases affecting millions across the globe, including retinitis pigmentosa, Stargardt disease, and geographic atrophy—late stage dry age-related macular degeneration. Discover more at www.ocugen.com and follow us on X and LinkedIn.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.
Contact:
Tiffany Hamilton
AVP, Head of Communications
Tiffany.Hamilton@ocugen.com
FAQ
When and where will Ocugen (OCGN) present at the Cell & Gene Meeting on the Mesa 2025?
What is Ocugen's (OCGN) goal for BLA submissions?
Who will represent Ocugen (OCGN) at the 2025 conferences?
What panel will Ocugen (OCGN) participate in at Chardan's Conference?
What is Ocugen's (OCGN) main focus in biotechnology?
